| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net cash provided by financing activities | 9,518 | 2,988 |
| Effect of exchange rate changes on cash and cash equivalents | 350 | 286 |
| Net increase in cash and cash equivalents | 20,654 | 13,927 |
| Cash and cash equivalents at beginning of period | 33,785 | - |
| Cash and cash equivalents at end of period | 54,439 | - |
ZEVRA THERAPEUTICS, INC. (ZVRA)
ZEVRA THERAPEUTICS, INC. (ZVRA)